Antibody Production Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Antibody Production Market Analysis

COVID-19 had a significant impact on the antibody production market. The government-imposed lockdowns, supply chain disruption, and trade bans in several countries significantly reduced antibody production during the initial phase of the pandemic. However, the emergency use authorization (EUA) for monoclonal antibodies as a treatment against COVID-19 by healthcare organizations increased the demand for antibody production in the industry. For instance, the United States COVID-19 Treatment Panel recommended the use of monoclonal antibodies for treating the SARS-CoV-2 variants, such as Bebtelovimab 175 mg intravenous injections, Bamlanivimab, etesevimab, and a few others. Therefore, the demand for antibodies has been increasing in the past few years. The trend is expected to continue in the forecast period owing to the long-term impact of COVID-19 on a person's health.

The major factors for the growth of the antibody production market include the rising adoption of targeted immunotherapy, the increase in the R&D expenditure of pharmaceutical and biotechnology companies, and the rising demand for therapeutic antibodies.

Antibodies are used in the treatment of various diseases, such as cancer, rheumatoid arthritis, and other chronic diseases. The targeted therapy is attaining importance due to its specificity toward cancer cells while sparing the toxicity to off-target cells. As there is a rising prevalence of cancer, targeted therapies are getting more attention. For instance, as per the Australian Institute of Health and Welfare (AIHW) 2021 report, a total of 150,782 new cancer cases were estimated in Australia in 2021. Out of the total number of cancer cases, breast cancer cases were estimated to be 20,030, lung cancer with 13,810 new cases, and prostate cancer 18,110 cases were estimated to occur in 2021. Some examples of monoclonal antibodies used in targeted therapies are bevacizumab, cetuximab, and ipilimumab. Hence with the high burden of cancer, the antibody production market is estimated to grow during the forecast period.

The rising adoption of targeted therapies is expected to propel the overall growth of the antibody production market over the forecast period. The success rates and blockbuster sales of biologics have also made large pharmaceutical companies shift their presence to biopharma. Over the past two decades, the chimerization and humanization of mAbs (monoclonal antibodies) have led to the approval of several drugs & therapies for the treatment of autoimmune diseases, cancer, and transplant rejection. For instance, in August 2022, the FDA approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable or metastatic HER2-low breast cancer. It is one of the first approved targeted therapy. Such approvals highlight the need and demand for the treatment of life-threatening diseases like breast cancer which is further expected to augment the market growth during the forecast period.

Therefore, owing to the factors such as the high prevalence of diseases requiring targeted therapies and rising product launches by key players, the studied market is anticipated to witness growth over the analysis period. However, the high cost involved in antibody production and stringent government regulations is expected to impede the growth of the market.

Antibody Production Market Trends

This section covers the major market trends shaping the Antibody Production Market according to our research experts:

The Monoclonal Antibodies Segment is Expected to Hold a Significant Market Share Over The Forecast Period

Antibody Production Industry Segmentation

As per the scope of the report, antibody production refers to the process of creating a specific antibody. In a broad sense, it consists of various methods, such as upstream, downstream, and filtration. The process involves the preparation of antigen samples, which are injected into the laboratory or farm animals to evoke high expression levels of antigen-specific antibodies in the serum, which are then recovered from the animal. The Antibody Production Market is Segmented by Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies, Other Antibody Types), Process (Upstream Processing, Downstream Processing, Filtration), End User (Pharmaceutical and Biotechnology Companies, Research Laboratories, Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.